Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28150271 | 0.78 | CHRM5 (0.37) | SMN1; SMN2LMNAADRA1AFABP3ESR1 | |
| SCHEMBL11796674 | 0.77 | LPAR2 (0.32) | SMN1; SMN2LPAR2LPAR3MAPTTSHR | |
| SCHEMBL65991 | 0.77 | FABP3 (0.39) | SMN1; SMN2LMNAADRA1AFABP3ESR1 | |
| SCHEMBL25857265 | 0.75 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAADRA1AFABP3ESR1 | |
| SCHEMBL29128926 | 0.74 | LPAR3 (0.50) | SMN1; SMN2LMNAADRA1AFABP3ESR1 | |
| SCHEMBL8598236 | 0.72 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAADRA1AFABP3ESR1 | |
| SCHEMBL22568210 | 0.72 | LPAR3 (0.60) | LMNAADRA1AFABP3ESR1ADORA3 | |
| SCHEMBL15778356 | 0.72 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAADRA1AFABP3ESR1 | |
| SCHEMBL27094907 | 0.71 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAADRA1AESR1ADORA3 | |
| SCHEMBL13101840 | 0.71 | FABP3 (0.37) | SMN1; SMN2LMNAADRA1AFABP3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273740-A1 | Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses | FLEMING RONALD A | 2010-10-28 | — | — | US | disclosed |
| WO-2005099719-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050187191-A1 | Methods and compositions for the treatment of respiratory syncytial virus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-25 | — | — | US | disclosed |
| US-20050187192-A1 | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses | KUCERA PHARMACEUTICAL COMPANY | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273740-A1 | Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 3818/4885LMNA 2883/4885ADRA1A 3807/4885 |
| US-20050187191-A1 | Methods and compositions for the treatment of respiratory syncytial virus | RNASEH1, MAVS, ZC3HAV1 | SMN1; SMN2 448/4885LMNA 1852/4885ADRA1A 4063/4885 |
| US-20050187192-A1 | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 3818/4885LMNA 2883/4885ADRA1A 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.